Radosław Polański
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
Estrogen and related hormone effects, Advanced Breast Cancer Therapies, Lung Cancer Research Studies, Cancer-related Molecular Pathways, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer(2014)688 cited
- → Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer(2013)348 cited
- → Vasculogenic mimicry in small cell lung cancer(2016)239 cited
- → Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist(2020)109 cited
- → p53 and MDM2 in renal cell carcinoma(2010)108 cited
- → The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance(2023)55 cited
- → MDM2 Regulates Dihydrofolate Reductase Activity through Monoubiquitination(2008)50 cited
- → Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists(2019)37 cited
- → Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy(2011)35 cited
- → MDM2 interacts with NME2 (non-metastatic cells 2, protein) and suppresses the ability of NME2 to negatively regulate cell motility(2011)27 cited